Patent ID: 9241896
Filing Date: 2016-01-26
CPC Classification: A61K

Claim Text:
1. An extended release pharmaceutical formulation in oral unit dosage form comprising about 43.3% w/w of N-acetylneuraminic acid (NeuAc) or a pharmaceutically acceptable salt thereof; about 25.5% w/w of hypromellose or about 25.5% w/w of polyethylene oxide; about 21.2% w/w of sodium alginate; and about 4.2% w/w of carrageenan; wherein the in vitro dissolution release profile of the formulation at intestinal pH is near linear, and the formulation contains about 325 mg to about 500 mg of NeuAc in each unit dosage and provides a steady plasma concentration of NeuAc upon three or four times of oral administration in 24 hours.